ClinicalTrials.gg
CompletedNCT05843617Updated Aug 1, 2024

Comparison of Bioavailability of Liposomal and Traditional Formulation of Vitamin C

An interventional study of Liposomal Vitamin C and Traditional Vitamin C in Bioavailability of Vitamin C, sponsored by AronPharma Sp. z o. o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2022, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of the study was to compare the profiles of vitamin C serum concentration in healthy volunteers after the single oral administration either in a liposomal or traditional formulation.

Read the detailed description

The randomized, double-blind, cross-over study was conducted under the supervision of physician on a group of 10 healthy subjects. The volunteers received 1g of vitamin C in a traditional formulation (powder in capsules), and after 14 days of a washout period 1 gram of liposomal formulation (powder in capsules). Venous blood was collected from each participant of the study immediately before the administration of a studied substance and 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 24 hours post the administration.

02

Conditions studied

  • Bioavailability of Vitamin C

Keywords

  • Ascorbic Acid
  • Liposomal Vitamin C
03

In context

Lead sponsor

AronPharma Sp. z o. o. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men, 18-65 years old.
  • Signed .
  • No injuries or hospitalizations within the last 3 months.
  • Refraining from consuming any vitamin C supplements or foods enriched with vitamin C for a period of 72 hours. Limiting excessive consumption of red peppers, parsley (stalks), Brussels sprouts, broccoli, turnip, tomatoes, cabbage, spinach, watercress, citrus fruits, and citrus juices. Not taking acetylsalicylic acid (aspirin, polopiryna, etopiryna) during the study.
  • Participants should fast for at least 8-12 hours prior to the administration of the preparations.

Exclusion criteria

Exclusion Criteria:

  • Unwilling to give consent.
  • Injuries within the last 3 months.
  • Cancer (current or past).
  • Renal dysfunction ( \< 60 ml/min).
  • Gastrointestinal disorders (including use of antacids).
  • Tobacco use in any form.
  • Pregnancy/breastfeeding.
  • Patient after organ transplantation, after a stroke, use of anticoagulants, use of .
  • Female patient receiving hormonal therapy ().
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Liposomal Vitamin C

    Single oral dose of liposomal vitamin C formulation

    Dietary Supplement: Liposomal Vitamin C

  • Active comparator
    Traditional Vitamin C

    Single oral dose of traditional vitamin C formulation

    Dietary Supplement: Traditional Vitamin C

Interventions

  • Dietary supplementAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1000 mg of ascorbic acid in liposomal formulation

  • Dietary supplementTraditional Vitamin C

    1000 mg of ascorbic acid in traditional formulation

06

What researchers measure

Primary outcomes

  1. Total amount of ascorbic acid that has been absorbed, defined as AUC

    Comparison of the bioavailability of formulations based on the total amount of ascorbic acid that has been absorbed, defined as AUC (area under the curve)

    Time frame: baseline, 30 minutes, 1, 2, 3, 4, 6, 8, 10, 24 hours post the administration

  2. Maximum concentration of ascorbic acid (Cmax)

    Maximum concentration of ascorbic acid achieved in the blood after administration of both formulations

    Time frame: baseline, 30 minutes, 1, 2, 3, 4, 6, 8, 10, 24 hours post the administration

Secondary outcomes

  1. Concentration of ascorbic acid after 24 hours (C24h)

    Comparison of the concentration achieved in the blood after 24 hours (C24h) from the administration of both formulations

    Time frame: 24 hours post the administration

07

Study locations

1 site
  • Medical University of Warsaw
    Warsaw, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jun 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Feb 28, 2022
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 9, 2022
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843617
Lead sponsor
AronPharma Sp. z o. o.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Feb 28, 2022
Primary completion
Jun 9, 2022
Completion
Jun 9, 2022
Last update
Aug 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion